News

Video

The TROPION-Breast01 Trial: Datopotamab Deruxtecan in HR+, HER2- Breast Cancer

Author(s):

Laura Huppert, MD,Yara Abdou, MD

The TROPION-Breast01 trial studied the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) in previously treated HR+, HER2- breast cancer patients and showed improved progression-free survival to 7 months compared to 4.5 months with standard chemotherapy, with less high grade toxicity observed with Dato-DXd.

Related Videos
Sheldon M. Feldman, MD
In this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer, highlighting the need for holistic care that addresses both physiological and psychological aspects of treatment while reinforcing the value of strong relationships between primary care physicians and specialists.
In this episode of OncChats: Empowering Community Cancer Care, Dr. Woodworth sheds light on the “Road to Recovery” survivorship program at Henry Mayo, which supports cancer survivors by providing them with fitness, education, and mental health resources, and underscores the importance of mentorship programs for community providers to ensure equitable cancer care.
In this episode of OncChats: Empowering Community Cancer Care, Drs Woodworth and Rai, discuss their collaborative approach to cancer screening, emphasizing the importance of community efforts and individual assessments in integrating genetic testing and screenings into routine practice.
In this episode of OncChats: Empowering Community Cancer Care, experts discuss the significance of community-based cancer care, emphasizing that most cancers are diagnosed locally and highlighting the importance of collaboration between primary care physicians and specialists to provide optimal education and treatment.
Sunil Adige, MD
Margaret E. Gatti-Mays, MD, MPH, FACP
Sunil Adige, MD
Seth Wander, MD, PhD
Related Content
Jairam Krishnamurthy, MD, FACP, of University of Nebraska Medical Center
October 25th 2024

Frontline Palbociclib Opens the Door to Subsequent CDK4/6 Inhibition in Metastatic Breast Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Jairam Krishnamurthy, MD, FACP, of University of Nebraska Medical Center
October 24th 2024

Adjuvant Ribociclib Revamps HR+/HER2– Breast Cancer Management

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

Ribociclib in breast cancer | Image Credit: © Axel Kock - stock.adobe.com
October 18th 2024

Ribociclib Earns Positive CHMP Opinion in HR+/HER2– Early Breast Cancer

Nancy Lin, MD
October 16th 2024

T-DXd Demonstrates Efficacy in HER2+ Metastatic Breast Cancer With Stable or Active Brain Metastases